Shih-Ping Cheng1, Ming-Nan Chien2, Tao-Yeuan Wang3, Jie-Jen Lee1, Chun-Chuan Lee2, Chien-Liang Liu4. 1. Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan; Graduate Institute of Medical Sciences and Department of Pharmacology, Taipei Medical University, Taipei, Taiwan. 2. Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan. 3. Department of Pathology, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan. 4. Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan. Electronic address: surg.mmh@gmail.com.
Abstract
BACKGROUND: The optimal extent of surgery for differentiated thyroid cancer may not be well recognized initially. Identification of intermediate-risk features on surgical pathology may prompt the need for completion thyroidectomy if a lobectomy is performed. In this study, we examined the factors in relation to the need for completion thyroidectomy. METHODS: We studied consecutive patients who underwent thyroidectomy for differentiated thyroid cancer from 2008 to 2017. Total thyroidectomy was indicated when tumor size >4 cm, clinical extrathyroidal extension, clinical lymph node metastasis, or distant metastasis was present. The need for completion thyroidectomy was defined as the presence of aggressive histology, extrathyroidal extension, lymphovascular invasion, or non-low-risk nodal metastasis. RESULTS: Among 771 patients, 155 (20%) were definitely indicated for total thyroidectomy. The need for completion thyroidectomy was identified in 273 (44%) of the 616 patients initially eligible for lobectomy. The proportions of patients requiring completion thyroidectomy were 18% and 57% for microcarcinomas and tumors of 1-4 cm, respectively. Receiver operating characteristic curve analysis indicated that tumor size ≥1.1 cm had the highest accuracy of prediction. Multivariate logistic regression revealed that tumor size and BRAF V600E mutation were independent factors predicting the risk of requiring completion thyroidectomy. CONCLUSION: A substantial portion of patients with differentiated thyroid cancer who are preoperatively eligible for lobectomy would be found to have intermediate-risk pathologic features. This should be incorporated into the shared decision making before surgery.
BACKGROUND: The optimal extent of surgery for differentiated thyroid cancer may not be well recognized initially. Identification of intermediate-risk features on surgical pathology may prompt the need for completion thyroidectomy if a lobectomy is performed. In this study, we examined the factors in relation to the need for completion thyroidectomy. METHODS: We studied consecutive patients who underwent thyroidectomy for differentiated thyroid cancer from 2008 to 2017. Total thyroidectomy was indicated when tumor size >4 cm, clinical extrathyroidal extension, clinical lymph node metastasis, or distant metastasis was present. The need for completion thyroidectomy was defined as the presence of aggressive histology, extrathyroidal extension, lymphovascular invasion, or non-low-risk nodal metastasis. RESULTS: Among 771 patients, 155 (20%) were definitely indicated for total thyroidectomy. The need for completion thyroidectomy was identified in 273 (44%) of the 616 patients initially eligible for lobectomy. The proportions of patients requiring completion thyroidectomy were 18% and 57% for microcarcinomas and tumors of 1-4 cm, respectively. Receiver operating characteristic curve analysis indicated that tumor size ≥1.1 cm had the highest accuracy of prediction. Multivariate logistic regression revealed that tumor size and BRAFV600E mutation were independent factors predicting the risk of requiring completion thyroidectomy. CONCLUSION: A substantial portion of patients with differentiated thyroid cancer who are preoperatively eligible for lobectomy would be found to have intermediate-risk pathologic features. This should be incorporated into the shared decision making before surgery.
Authors: Edwina C Moore; Samuel Zolin; Vikram Krishnamurthy; Judy Jin; Joyce Shin; Eren Berber; Allan Siperstein Journal: World J Surg Date: 2020-02 Impact factor: 3.352
Authors: Steven J Craig; Andrew M Bysice; Steven C Nakoneshny; Janice L Pasieka; Shamir P Chandarana Journal: Thyroid Date: 2020-01-09 Impact factor: 6.568
Authors: Malik Azhar; Faisal Aziz; Salama Almuhairi; Mohammad Alfelasi; Ali Elhouni; Rizwan Syed; Humaid O Al-Shamsi; Khaled M Aldahmani Journal: Ann Med Surg (Lond) Date: 2021-03-04
Authors: Dana M Hartl; Joanne Guerlain; Ingrid Breuskin; Julien Hadoux; Eric Baudin; Abir Al Ghuzlan; Marie Terroir-Cassou-Mounat; Livia Lamartina; Sophie Leboulleux Journal: Cancers (Basel) Date: 2020-11-06 Impact factor: 6.639